Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry May Like FDA's Biosimilar Guidance Withdrawal, But Not The New Information Vacuum

Executive Summary

Sponsors may have to rely even more on the advice they receive from formal meetings as FDA decides to rewrite draft guidance on statistical approaches to evaluate analytical similarity for biosimilars.

You may also be interested in...



Biosimilars: US FDA Favors Quality Range Testing For Comparative Analytical Assessments

New draft guidance on statistical approaches eliminates previous recommendations on tiered ranking and statistical equivalence testing of product quality attributes, giving biosimilar sponsors more flexibility.

Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda

US FDA plans new guidances on real-world data, clinical trial statistics, and patient input in coming this year.

Biosimilar Hearing Will Consider Whether 'Umbrella' Exclusivity Policy Warranted

US FDA asks for comments on whether the policy employed for small molecule generics also should apply to biosimilars.

Related Content

Topics

UsernamePublicRestriction

Register

PS123350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel